SCHEMBL4289701

SCHEMBL4289701

Nc1c(Cl)cc(C(=O)Nc2nccs2)cc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
RECQL P46063 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ADORA2A P29274 3/20 0.51
ADORA1 P30542 3/20 0.51
DDAH1 O94760 1/20 0.50
PIK3CD O00329 1/20 0.49
PIK3C2B O00750 1/20 0.49
AURKA O14965 1/20 0.49
PIK3C2G O75747 1/20 0.49
CDK1 P06493 1/20 0.49
CDK4 P11802 1/20 0.49
CCND1 P24385 1/20 0.49
CDK2 P24941 1/20 0.49
MAPK3 P27361 1/20 0.49
MAPK1 P28482 1/20 0.49
CCND3 P30281 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4297483 0.81 ADORA2A (0.62) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL4297480 0.81 RAB9A (0.61) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL4291882 0.79 ADORA2A (0.78) NPC1RAB9ASMN1; SMN2ADORA2AADORA1
SCHEMBL3196687 0.77 NPC1 (0.62) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL3200155 0.76 RAB9A (0.66) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL8797071 0.75 NPC1 (0.62) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL4299674 0.74 RAB9A (0.62) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL3891438 0.73 SMN1; SMN2 (0.58) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL13122950 0.73 RAB9A (0.56) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL8797043 0.72 RAB9A (0.62) NPC1RAB9ASMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 NPC1 1022/4885RAB9A 2380/4885SMN1; SMN2 1617/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 NPC1 1022/4885RAB9A 2380/4885SMN1; SMN2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.